Skip to main content

Table 4 Tumor Response by Immune-Related Adverse Event Occurrence

From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Best Responsea

irAE, n = 130 pts

No irAE, n = 1405 pts

Complete Response (CR)

8 (6.2%)

67 (4.8%)

Partial Response (PR)

37 (28.5%)

239 (17%)

Stable Disease (SD)

48 (37%)

483 (34.4%)

Progressive Disease

32 (25%)

470 (33.5%)

Missing

5 (3.8%)

146 (10.4%)

CR + PR + SD (n, %)

93 (71%)

789 (56%)

bp = 0.0008

CR + PR (n, %)

45 (34.6%)

306 (21.8%)

cp = 0.0014

  1. irAE immune-related adverse event; pts.-patients;
  2. aBest response is determined from responses captured between baseline IL-2 administration and prior to subsequent treatment
  3. bFisher’s exact test comparing CR + PR + SD by irAE to no irAE
  4. cFisher’s exact test comparing best response by irAE to no irAE
Back to article page